Lisata Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LSTA Nasdaq 2836 www.lisata.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lisata Therapeutics, Inc.

LSTA Releases Valuations Report on Level 3 Loans - Dec 4th, 2025 7:00 am
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... - Nov 6th, 2025 10:00 pm
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 6th, 2025 2:05 pm
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ - Nov 6th, 2025 6:00 am
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Nov 4th, 2025 2:00 pm
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - Oct 30th, 2025 6:00 am
Lisata Therapeutics to Present at LD Micro Main Event XIX - Oct 13th, 2025 6:00 am
Lisata Therapeutics Partners with Catalent on ADC Technology - Oct 9th, 2025 9:16 am
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - Oct 8th, 2025 6:30 am
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth? - Oct 3rd, 2025 9:52 am
Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer Study - Sep 30th, 2025 1:04 pm
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial - Sep 29th, 2025 6:00 am
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 6:00 am
LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets Investments - Aug 7th, 2025 3:33 pm
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 7th, 2025 2:05 pm
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 - Jul 31st, 2025 6:00 am
Lisata Secures New Composition of Matter Patent for Certepetide - Jul 17th, 2025 12:58 pm
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update - Jul 17th, 2025 6:00 am
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide - Jul 15th, 2025 6:00 am
Lisata Reports Survival, Response Benefits With Certepetide in Pancreatic Cancer Trial - Jun 26th, 2025 9:58 am